Medivir: OLYSIO Sales During The First Quarter 2016

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the global first quarter net sales of OLYSIO® (simeprevir) amounted to 32 MUSD.

The royalty for the first quarter amounted to 18 MSEK (2.0 MEUR). Medivir’s royalties based on sales for the first quarter are calculated from the first royalty tier.

Back to news